Search Results
Response Data from the JULIET Trial in DLBCL
JULIET trial update: Myc expression and T-cell responses in R/R DLBCL
Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-cell lymphoma
Updated JULIET results for tisagenlecleucel in DLBCL
Safety Data in Phase II JULIET Trial in DLBCL
Latest results from JULIET: Tisagenlecleucel in adults with DLBCL
Long term data from JULIET trial, using tisagenlecleucel for patients with relapsed or treatment...
Using AI to predict patient response to CAR-T cell therapy: analysis of the JULIET trial
Relapsed/Refractory B-cell Lymphomas in the CAR-T Era: Improving Outcomes in a Population at Need
Stephen J. Schuster, MD: Tisagenlecleucel Promising in Relapsed/Refractory DLBCL
Richard Maziarz, MD: Tisagenlecleucel induces durable response among adults with pretreated DLBCL
Six-month analysis of tisagenlecleucel in stubborn form of lymphoma shows sustained responses
